Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 469 | 28% |
| 2020 | 5 | 425 | 30% |
| 2021 | 6 | 387 | 32% |
| 2022 | 5 | 373 | 35% |
| 2023 | 4 | 381 | 38% |
| 2024 | 4 | 431 | 39% |
| 2025 from claims | – | 509 411–597 | 40% |
| 2026 forecast | – | 530 415–665 | 39% |
| 2027 forecast | – | 544 403–719 | 40% |
| 2028 forecast | – | 558 395–771 | 40% |
| 2029 forecast | – | 573 390–822 | 40% |
| 2030 forecast | – | 588 386–873 | 40% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Massachusetts; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 3 | 512+0.8%/yr | +0.8%/yr | 0.3 | 0% | 600 in 2030+2.7%/yr |
| Pennsylvania | 3 | 418+0.9%/yr | +0.9%/yr | 0.3 | 0% | 330 in 2030−3.7%/yr |
| New Jersey | 0 | 107−1.1%/yr | −1.1%/yr | 0.1 | 0% | 120 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 117 | 7,183−0.3%/yr | −0.3%/yr | 8.00.9× | 12% | 8,190 in 2030+2.2%/yr |
| Tumor & fibroid embolization | 12 | 677+16%/yr | +16%/yr | 0.71.2× | 46% | 1,170 in 2030+9.5%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Angiodynamics leads with 47% of company spending on these surgeons in 2025, level with 2024.
In 2025, 20 companies reported engagement with Massachusetts’s surgeons worth $767K in consulting, speaking, meals and travel tied to these products, about $192K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.